Safe treatment of seizures in the setting of HIV/AIDS

Current Treatment Options in Neurology

Volumn 15, Issue 4, 2013, Pages 529-543

  Siddiqi, Omar ^a,b   Birbeck, Gretchen L ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Acute management; AIDS; Antiepileptic drugs; Antiretroviral medications; Cerebrovascular disease; Chronic management; Epilepsy; Highly active antiretroviral therapy; HIV; HIV viremia; Opportunistic infections; Safe treatment; Seizure; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CARBAMAZEPINE; CLOBAZAM; EFAVIRENZ; ETIRACETAM; ETRAVIRINE; FELBAMATE; GABAPENTIN; HARKOSERIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMOTRIGINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZIDOVUDINE; ZONISAMIDE;

ABNORMAL BEHAVIOR; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; APLASTIC ANEMIA; ARTICLE; ASTHENIA; ATAXIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID EXAMINATION; CEREBROVASCULAR DISEASE; CRYPTOCOCCAL MENINGITIS; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; EPILEPSY; FATIGUE; FOCAL EPILEPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIPPOCAMPAL SCLEROSIS; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERLIPIDEMIA; HYPONATREMIA; INFECTION; IRRITABILITY; KETOGENIC DIET; LIFESTYLE MODIFICATION; LIVER FAILURE; LUMBAR PUNCTURE; MENTAL INSTABILITY; MONOTHERAPY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROTOXICITY; NYSTAGMUS; PANCREATITIS; PATIENT COMPLIANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE; TEMPORAL LOBECTOMY; TONIC CLONIC SEIZURE; TOXOPLASMOSIS; TREMOR; TUBERCULOUS MENINGITIS; VAGUS NERVE STIMULATION; VIRUS LOAD; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84882267968     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0237-6     Document Type: Article

References (78)

1. WHO. Gobal Summary of the AIDS epidemic 2011. 2011. Available at: http://www.who.int/hiv/data/2012-epi-core-en.png Accessed February 9, 2013.
2. UNAIDS. UNAIDS United States of America. 2013. Available at: http://www.unaids.org/en/regionscountries/countries/unitedstatesofamerica / Accessed February 9, 2013.
3. Aarli JA, Diop AG, Lochmuller H. Neurology in sub-Saharan Africa: a challenge for World Federation of Neurology. Neurology. 2007;69(17):1715-8.
4. Sinha S, Satishchandra P, Nalini A, et al. New-onset seizures among HIV infected drug naïve patients from south India. Neuro Asia. 2005;10:29-33.
5. Kellinghaus C, Engbring C, Kovac S, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008;17(1):27-33.
6. Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology. and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78(2):139-45. This evidence-based guideline which was jointly endorsed by the American Academy of Neurology, the World Health Organization and the American Epilepsy Society provides a detailed review of the information to date on drug interactions between AEDs and ARVs as well as graded classification of the evidence.
7. Bhanushali MJ, Helmers SJ. Diagnosis and acute management of seizures in adults. Hosp Phys. 2008;48:37-42.
8. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 1992;326(10):668-72.
9. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc Res Treat. 2011;2011:798764.
10. Garcia-Monco JC. Central nervous system tuberculosis. Neurol Clin. 1999;17(4):737-59.
11. Bharucha NE, Raven RH, Nambiar VK. Review of seizures and status epilepticus in HIV and tuberculosis with preliminary view of Bombay hospital experience. Epilepsia. 2009;50 Suppl 12:64-6.
12. Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA. 1979;241(3):264-8.
13. Sutlas PN, Unal A, Forta H, et al. Tuberculous meningitis in adults: review of 61 cases. Infection. 2003;31(6):387-91.
14. Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, et al. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia. 2012;173(5-6):321-7.
15. Dore GJ, Law MG, Brew BJ. Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection. J Neuro-AIDS. 1996;1(4):59-69.
16. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol. 1990;47(6):640-2.
17. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006;66(2):262-4.
18. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990;112(1):35-49.
19. Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med. 1993;94(2):169-74.
20. Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA. 1990;263(7):973-8.
21. Benjamin LA, Bryer A, Emsley HC, et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11(10):878-90. This is an excellent review of the epidemiology and pathophysiology of stroke in people with HIV, which also offers considerations for future research directions.
22. Nijhawan AE, Zachary KC, Kwara A, Venna N. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. AIDS Read. 2008;18(7):386-8. C383.
23. Strehlau R, Martens L, Coovadia A, et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011;30(11):1001-3.
24. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61(2):148-54.
25. Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453-61.
26. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G- > T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357-65.
27. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300.
28. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. Am J Med. 1989;87(2):173-7.
29. Portegies P, Berger JR. HIV/AIDS and the nervous system. Edinburgh: Elsevier; 2007.
30. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol. 2005;64(6):529-36.
31. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147 Suppl 1:S232-40.
32. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett. 2011;497(3):223-30.
33. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. Available at: http://aidsinfo.nih. gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. Accessed Februrary 18, 2013.
34. Lowenstein DH. Status epilepticus: an overview of the clinical problem. Epilepsia. 1999;40 Suppl 1:S3-8. discussion S21-2.
35. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-2.
36. Beghi E. Treating epilepsy across its different stages. Ther Adv Neurol Disord. 2010;3(2):85-92.
37. Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia. 2008;49 Suppl 1:13-8.
38. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41(7):965-72.
39. Kim LG, Johnson TL, Marson AG, Chadwick DW, MMS. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006;5(4):317-22.
40. L'Homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43(2):193-6.
41. Ji P, Damle B, Xie J, Unger SE, et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48(8):948-56.
42. Okulicz JF, Grandits GA, French JA, et al. Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther. 2011;8:18.
43. Jennings HR, Romanelli F. The use of valproic acid in HIV-positive patients. Ann Pharmacother. 1999;33(10):1113-6.
44. Romanelli F, Jennings HR, Nath A, et al. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology. 2000;54(7):1404-7.
45. Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol. 1996;77(Pt 9):1993-9.
46. Witvrouw M, Schmit JC, Van Remoortel B, et al. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retrovir. 1997;13(2):187-92.
47. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS. 2008;22(10):1125-9.
48. Yacoob Y, Bhigjee AI, Moodley P, Parboosing R. Sodium valproate and highly active antiretroviral therapy in HIV positive patients who develop new onset seizures. Seizure. 2011;20(1):80-2.
49. DiCenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48(11):4328-31.
50. Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994;56(3):272-8.
51. van der Lee MJ, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80(2):159-68.
52. van Luin M, Colbers A, Verwey-van Wissen CP, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49(10):1220-7.
53. Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-92.
54. Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007;48(3):435-41.
55. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32(3):194-209.
56. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36(4):289-304.
57. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother. 1999;33(4):461-73.
58. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473-81.
59. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347-56.
60. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-55.
61. Liedtke MD, Lockhart SM, Rathbun RC. Anticonvulsant and antiretroviral interactions. Ann Pharmacother. 2004;38(3):482-9.
62. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24(1):91-103.
63. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61(9):1218-21.
64. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20(4):725-7.
65. Nizam A, Mylavarapu K, Thomas D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia. 2011;52(10):e153-5.
66. Halford JJ, Lapointe M. Clinical perspectives on lacosamide. Epilepsy Curr. 2009;9(1):1-9.
67. Zaccara G, Perucca P, Loiacono G, et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2013;54(1):66-74.
68. McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clin Ther. 2003;25(5):1382-406.
69. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(6 Suppl 5):S17-22. discussion S31-12.
70. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-8.
71. Picot MC, Neveu D, Kahane P, et al. Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy - preliminary results. Rev Neurol. 2004;160(Spec No 1):5S354-67.
72. Silfvenius H. Cost and cost-effectiveness of epilepsy surgery. Epilepsia. 1999;40 Suppl 8:32-9.
73. Widjaja E, Li B, Schinkel CD, et al. Cost-effectiveness of pediatric epilepsy surgery compared with medical treatment in children with intractable epilepsy. Epilepsy Res. 2011;94(1-2):61-8.
74. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. 2011;115(6):1248-55.
75. Boon P, Vonck K, D'Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg. 1999;99(4):275-80.
76. Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol. 2001;18(5):419-28.
77. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007;48(1):43-58.
78. Kossoff EH, Rowley H, Sinha SR, Vining EP. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia. 2008;49(2):316-9.